New MRI technology for assessing kidney dysfunction

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study explores the use of advanced magnetic resonance imaging (MRI) technology to non-invasively evaluate renal insufficiency and renal fibrosis. Traditional methods like renal biopsy are invasive and carry risks, while MRI offers a safer alternative with high-resolution imaging capabilities. The goal is to develop a comprehensive assessment method that can improve the diagnosis and monitoring of kidney diseases, particularly chronic kidney disease (CKD) and acute kidney injury (AKI). By utilizing multi-parameter analysis, this approach aims to provide a more accurate understanding of kidney pathology without the complications associated with invasive procedures.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with clinically suspected or confirmed renal insufficiency and prescribed MR examination;
2. Age/gender: no limit;
3. Patients who voluntarily participate in clinical trials and sign written informed consent forms

Exclusion Criteria:

1. Patients with pacemakers of unknown material, metal implants in the body, neurostimulators, and claustrophobia, etc.
2. Patients who cannot tolerate sufficient breath-holding for adequate MR examination

Where it's running

• Tongji hospital, NO.1095 jiefang avenue
  Wuhan, Hubei, China Recruiting

Study contacts

• Study coordinator: Zhen Li, Doctor
• Email: zhenli@hust.edu.cn
• Phone: 02783663543

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Clazakizumab for adults with high hsCRP at risk for a heart event

  This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.

  Recruiting at 32 sites Phase 2 Eli Lilly and Company · Huntsville, Alabama and 45 other locations · NCT07783802

• Living with CKD as a woman of childbearing age without dialysis or transplant

  This study asks how women aged 18 and up with chronic kidney disease, not on kidney replacement therapy, experience living with the condition.

  Recruiting University Hospital, Caen · Caen · NCT07690202

• Balcinrenone plus dapagliflozin vs dapagliflozin alone in CKD stages 3b-4

  This study tests whether balcinrenone combined with dapagliflozin works better than dapagliflozin alone in adults with CKD stage 3b–4.

  Recruiting at 33 sites Phase 3 AstraZeneca · Huntsville, Alabama and 477 other locations · NCT07624305

• Exercise during hemodialysis to prevent muscle loss and improve sleep

  This trial will test if a 12-week supervised exercise program performed during dialysis can improve muscle mass, strength, physical performance, sleep quality, and quality of life for patients aged 40 and over on chronic hemodialysis.

  Recruiting University of Salamanca · Salamanca, Salamanca · NCT07447375

• Home-based exercise to boost fitness for people waiting for a kidney transplant

  This study tests whether a 12-week, home-based exercise program plus a wearable activity tracker helps adults on the kidney transplant waiting list increase daily activity and improve physical function.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07446296

• Transformative 2.0 for diabetic kidney disease

  This project will try to see if adults with diabetic kidney disease who take SGLT2 diabetes medicines have different biological patterns in archived kidney tissue than similar people who do not take these medicines.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07444203

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.